Exelixis launches XL092 combination cohort in early-stage solid tumor study

• Exelixis (NASDAQ:EXEL) has enrolled the first patient into the dose-escalation cohort of the combination arm of the Phase 1 trial  evaluating XL092 alone and in combination with Genentech's atezolizumab (TECENTRIQ) in patients with advanced solid tumors.
• Initiated in February 2019, the dose-escalation evaluation of the XL092 monotherapy arm of Phase 1 trial is ongoing, after recommended doses of both single-agent XL092 and XL092 in combination with atezolizumab are established, the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell renal cell carcinoma, hormone-receptor positive breast cancer and metastatic castration-resistant prostate cancer.
• XL092 is an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER and other kinases.
• https://seekingalpha.com/news/3625740-exelixis-launches-xl092-combination-cohort-in-early-stage-solid-tumor-study